Oligomannate
China green lights first novel Alzheimer’s therapy since 2003
November 4, 2019Sales and Marketing Alzheimer's, China, Green Valley, Oligomannate, pharma
Shanghai Green Valley Pharmaceuticals has announced that its therapy Oligomannate (GV-971) has secured marketing approval from China’s National Medical Products Administration (NMPA) …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
